PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Alterations in cell cycle regulators have been implicated in human malignancies including breast cancer. PD 0332991 is an orally active, highly selective inhibitor of the cyclin D kinases (CDK)4 and CDK6 with ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. To identify predictors of response, we determined the in vitro sensitivity to PD 0332991 across a panel of molecularly characterized human breast cancer cell lines. METHODS: Forty-seven human breast cancer and immortalized cell lines representing the known molecular subgroups of breast cancer were treated with PD 0332991 to determine IC50 values. These data were analyzed against baseline gene expression data to identify genes associated with PD 0332991 response. RESULTS: Cell lines representing luminal estrogen receptor-positive (ER+) subtype (including those that are HER2 amplified) were most sensitive to growth inhibition by PD 0332991 while nonluminal/basal subtypes were most resistant. Analysis of variance identified 450 differentially expressed genes between sensitive and resistant cells. pRb and cyclin D1 were elevated and CDKN2A (p16) was decreased in the most sensitive lines. Cell cycle analysis showed G0/G1 arrest in sensitive cell lines and Western blot analysis demonstrated that Rb phosphorylation is blocked in sensitive lines but not resistant lines. PD 0332991 was synergistic with tamoxifen and trastuzumab in ER+ and HER2-amplified cell lines, respectively. PD 0332991 enhanced sensitivity to tamoxifen in cell lines with conditioned resistance to ER blockade. CONCLUSIONS: These studies suggest a role for CDK4/6 inhibition in some breast cancers and identify criteria for patient selection in clinical studies of PD 0332991
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some of these models, resistance can be overcome by including CDK4/6 inhibitors in the treatment (Finn et al., 2009; Goel et al., 2016; Kwong et al., 2012; Vora et al., 2014; Zhou et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Finn et al., 2009
In the citing paper
“Preclinical data utilizing palbociclib demonstrated the substantial sensitivity of hormone receptor (HR)-positive cell lines, compared to HR-negative cell lines, in part related to a higher incidence of RB-negativity in the latter breast cancer subgroup (81).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab has been shown to have clinical activity in HER2amplified breast cancer [34].”
BackgroundSelf-citationSørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Multiple drug effect analysis was performed using computer software as previously described [33].”
MethodA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 1×
“PD 0332991 is an orally active potent and highly selective inhibitor of CDK4 and CDK6 kinases, which in low nanomolar concentrations blocks pRb phosphorylation - subsequently inducing G1 arrest in sensitive cell lines [26-29].”
Background
Research works printed but not linked: 1
- Duchnowska RJJ Thorat MA Morimiya A Sledge GW Li L Biernat W Szczylik C Steeg PS Badve SS Gene expression analysis for prediciton of early brain metastasis in HER2-positive breast cancer patients [abstract 1019] J Clin Oncol 2008 26 20 Suppl abstract 1019
Cited by
Items 701–800 of 1,000
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer
Månsson‐Broberg, A., Geisler, J., TUOHINEN, S. S., Skyttä, T., Hrafnkelsdóttir, Þ. J., Nielsen, K. M., Hedayati, E., Omland, T., Offersen, B. V., Lyon, A. R., et al. (2020) · Current Heart Failure Reports · doi:10.1007/s11897-020-00486-8 · Cited by 28
Zhu, W., & Xu, B. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0795-4 · Cited by 22
Haley, B., Batra, K., Sahoo, S., Froehlich, T. W., Klemow, D., Unni, N. G., Ahn, C. W., Rodriguez, M., Hullings, M. A., & Frankel, A. E. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.03.005 · Cited by 23
Shariati, M., Evans, K. W., Zheng, X., Bristow, C. A., Ng, P. K., Rizvi, Y. Q., Tapia, C., Yang, F., Carugo, A., Heffernan, T. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01819-0 · Cited by 20
The DNA damage repair landscape in Black women with breast cancer
Mazumder, A., Jimenez, A., Ellsworth, R. E., Freedland, S. J., George, S. H. L., Bainbridge, M. N., & Haricharan, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221075458 · Cited by 22
Nicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 24
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
Mahgoub, T., Eustace, A. J., Collins, D. M., Walsh, N., O’Donovan, N., & Crown, J. P. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3097 · Cited by 21
BELL, T. J., Crown, J. P., Láng, I., Bhattacharyya, H., Zanotti, G., Randolph, S., Kim, S., Huang, X., Bartlett, C. H., Finn, R. S., et al. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2016.1157060 · Cited by 21
New agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 22
Hormone-Targeted Therapy and Resistance
Metcalfe, C., Friedman, L. S., & Hager, J. H. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050512 · Cited by 20
Stelitano, D., Leticia, Y. P., Dalla, E., Monte, M., Piazza, S., & Schneider, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18691 · Cited by 32
Palbociclib enhances activin‐ SMAD ‐induced cytostasis in estrogen receptor‐positive breast cancer
Harada, M., Morikawa, M., Ozawa, T., Kobayashi, M., Tamura, Y., Takahashi, K., Tanabe, M., Tada, K., Seto, Y., Miyazono, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13841 · Cited by 22
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
Hou, Y., Ji, K., Sun, Y., Zhang, L.-N., & Chen, J. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2026-9 · Cited by 22
A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 25
Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC
Digiacomo, G., Volta, F., Garajová, I., Balsano, R., & Cavazzoni, A. (2021) · Life · doi:10.3390/life11080843 · Cited by 22
Saikia, S., Kolita, B., Dutta, P. P., Dutta, D. J., Neipihoi, Nath, S., Bordoloi, M., Quân, P. M., Thuy, T. T., Phương, D. L., et al. (2015) · Steroids · doi:10.1016/j.steroids.2015.06.012 · Cited by 21
Effects of an Indolocarbazole-Derived CDK4 Inhibitor on Breast Cancer Cells
Sun, Y., Li, Y., Wu, H., Wu, S.-H., Wang, Y., Luo, D., & Liao, D. J. (2011) · Journal of Cancer · doi:10.7150/jca.2.36 · Cited by 27
Gao, T., Sun, Y., Leng, P., Liu, D., Guo, Q., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549520 · Cited by 34
Palbociclib for the treatment of postmenopausal breast cancer – an update
Steger, G. G., Gnant, M., & Bartsch, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133590 · Cited by 21
Petrossian, K., Kanaya, N., Lo, C., Hsu, P.-Y., Nguyen, D. M., Yang, L., Yang, L., Warden, C., Wu, X., Pillai, R. K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25552 · Cited by 23
Kishino, E., Ogata, R., Saitoh, W., Koike, Y., Ohta, Y., Kanomata, N., & Kurebayashi, J. (2019) · Breast Cancer · doi:10.1007/s12282-019-01035-5 · Cited by 22
Jurić, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaïh, A., Lamfers, M. L. M., Hopkins, A. M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04050-7 · Cited by 22
Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
Aliagas, E., Alay, A., Martínez‐Iniesta, M., Hernández-Madrigal, M., Cordero, D., Gausachs, M., Pros, E., Saigí, M., Busacca, S., Sharkley, A. J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01547-y · Cited by 22
Mohammadalipour, A., Diaz, M. F., Livingston, M. K., Ewere, A., Zhou, A. L., Horton, P. D., Olamigoke, L. T., Lamar, J. M., Hagan, J. P., Lee, H. J., et al. (2022) · FASEB BioAdvances · doi:10.1096/fba.2021-00055 · Cited by 24
Harbeck, N., Burstein, H. J., Hurvitz, S. A., Johnston, S. R. D., & Vidal, G. A. (2022) · Cancer · doi:10.1002/cncr.34161 · Cited by 28
CDK 4/6 inhibitors for the treatment of meningioma
Young, J. S., Kidwell, R. L., Zheng, A., Haddad, A. F., Aghi, M. K., Raleigh, D. R., Schulte, J. D., & Butowski, N. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.931371 · Cited by 23
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition
Hu, Q., & Huang, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108939 · Cited by 26
Gower, A. C., Spira, A. E., & Lenburg, M. E. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-381 · Cited by 20
Targeted adjuvant therapy in breast cancer
Zardavas, D., Tryfonidis, K., Goulioti, T., & Piccart, M. J. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1247698 · Cited by 22
Thwaites, M. J., Cecchini, M. J., Passos, D. T., Welch, I. D., & Dick, F. A. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00561-16 · Cited by 21
Sau, M. C., Rajesh, Y., Mandal, M., & Bhattacharjee, M. (2018) · ChemistrySelect · doi:10.1002/slct.201800177 · Cited by 20
Odan, N., Kikawa, Y., Matsumoto, H., Minohata, J., Suwa, H., Hashimoto, T., Okuno, T., Miyashita, M., Saito, M., Yamagami, K., et al. (2020) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223420983843 · Cited by 22
An E2F1-HOXB9 Transcriptional Circuit Is Associated with Breast Cancer Progression
Zhussupova, A., Hayashida, T., Takahashi, M., Miyao, K., Okazaki, H., Jinno, H., & Kitagawa, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105285 · Cited by 22
Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
Beykou, M., Arias-García, M., Roumeliotis, T. I., Choudhary, J. S., Moser, N., Georgiou, P., & Bakal, C. (2022) · Scientific Data · doi:10.1038/s41597-022-01512-1 · Cited by 19
Heilmann, T., Dittmann, L., van Mackelenbergh, M., Mundhenke, C., Weimer, J. P., Arnold, N., Maass, N., & Schem, C. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4104-z · Cited by 19
Matikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
Are We Ready to Use ESR1 Mutations in Clinical Practice
Jeselsohn, R. M. (2017) · Breast Care · doi:10.1159/000481428 · Cited by 19
Lin, C., Lee, L., Wang, T., Hsu, C., Tsai, C.-L., Chao, A., & Lai, C. (2019) · Cancers · doi:10.3390/cancers11071025 · Cited by 20
Satriyo, P. B., Su, C. M., Ong, J. R., Huang, W.-C., Fong, I.-H., Lin, C.-C., Aryandono, T., Haryana, S. M., Deng, L., Huang, C.-C., et al. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115493 · Cited by 19
Estepa‐Fernández, A., García‐Fernández, A., Lérida‐Viso, A., Morellá‐Aucejo, Á., Esteve‐Moreno, J. J., Blandez, J. F., Alfonso, M., Candela‐Noguera, V., Vivo‐Llorca, G., Sancenón, F., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101692 · Cited by 20
Ngamphaiboon, N., Pattaranutaporn, P., Lukerak, S., Siripoon, T., Jinawath, A., Arsa, L., Shantavasinkul, P. C., Taonam, N., Trachu, N., Jinawath, N., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2303 · Cited by 21
Poulet, S., Dai, M., Wang, N., Yan, G., Boudreault, J., Daliah, G., Guillevin, A., Nguyen, H., Galal, S., Ali, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02029-4 · Cited by 24
Sen, S. R., Bunda, S., Shi, J., Wang, A., Mitts, T. F., & Hinek, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269944 · Cited by 21
A novel targeted therapy in breast cancer: cyclin dependent kinase inhibitors.
Akın, S., Babacan, T., Sarici, F., & Altundağ, K. (2014) · PubMed · Cited by 24
Does CDKN2A Loss Predict Palbociclib Benefit?
Gao, J. J., Adams, R. P., & Swain, S. M. (2015) · Current Oncology · doi:10.3747/co.22.2700 · Cited by 19
Hoeflich, K. P., Guan, J., Edgar, K. A., O'Brien, C. L., Savage, H. M., Wilson, T. R., Neve, R. M., Friedman, L. S., & Wallin, J. J. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.100 · Cited by 19
Jackson, R., Veroli, G. Y. D., Koh, S., Goldlust, I. S., Richards, F. M., & Jodrell, D. I. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005529 · Cited by 19
Hirakawa, T., Nasu, K., Aoyagi, Y., Takebayashi, K., & Narahara, H. (2017) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-017-0272-3 · Cited by 20
Zhang, G., Ma, F.-E., Li, L., Li, J., Li, P., Zeng, S., Sun, H., & Li, E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.02.017 · Cited by 20
Wang, L., Gao, S., Li, D., Ran, X., Sheng, Z., Wu, W., & Yang, X. (2019) · The Breast Journal · doi:10.1111/tbj.13703 · Cited by 20
Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer
Martín, M., García-Sáenz, J. Á., Manso, L., Llombart‐Cussac, A., Cassinello, A., Atienza, M., Ringeisen, F. P., & Ciruelos, E. (2020) · Future Oncology · doi:10.2217/fon-2020-0604 · Cited by 20
Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management
Beddok, A., Cottu, P. H., Fourquet, A., & Kirova, Y. (2021) · Cancers · doi:10.3390/cancers13246358 · Cited by 19
Androgen blockade based clinical trials landscape in triple negative breast cancer
Shi, Y., Yang, F., Huang, D., & Guan, X. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.05.004 · Cited by 20
Foffano, L., Cucciniello, L., Nicolò, E., Migliaccio, I., Noto, C., Reduzzi, C., Malorni, L., Cristofanilli, M., Gerratana, L., & Puglisi, F. (2024) · The Breast · doi:10.1016/j.breast.2024.103863 · Cited by 21
Luo, L., Wang, Y., Bui, T. N., Jiang, X., Chen, M., Rao, X., Mohammadhosseinpour, S., Li, M., Kim, S., Kim, R. Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67865-4 · Cited by 23
CDK4/6 inhibitor: from quiescence to senescence
Yoshida, A., & Diehl, J. A. (2015) · Oncoscience · doi:10.18632/oncoscience.256 · Cited by 18
ERα and ERβ co-expression: An indicator of aggressive tumors and hormonal sensitivity
Oueslati, M. H., Bittaieb, I., Sassi, N., Jemaa, A. B., Gamoudi, A., Rahal, K., & Oueslati, R. (2017) · Oncology Letters · doi:10.3892/ol.2017.6314 · Cited by 22
Senolysis Reduces Senescence in Veins and Cancer Cell Migration
Estepa‐Fernández, A., Alfonso, M., Morellá‐Aucejo, Á., García‐Fernández, A., Lérida‐Viso, A., Lozano‐Torres, B., Galiana, I., Soriano‐Teruel, P. M., Sancenón, F., Orzáez, M., et al. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100149 · Cited by 20
Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2
Jeselsohn, R. M., Schiff, R., & Grinshpun, A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.007 · Cited by 18
The Effects of HER2 on CDK4/6 Activity in Breast Cancer
Sinclair, W., & Cui, X. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.08.007 · Cited by 21
Liquid biopsies to predict CDK4/6 inhibitor efficacy and resistance in breast cancer
Main, S. C., Cescon, D. W., & Bratman, S. V. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.37 · Cited by 24
Alsaleh, K. A., Zahwahry, H. A., Bounedjar, A., Oukkal, M., Saadeddine, A., Mahfouf, H., Bouzid, K., Bensalem, A., Filali, T., Abdel‐Razeq, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04588-3 · Cited by 19
Xu, Q., Pan, G., Wang, Z., Wang, L., Tang, Y., Dong, J., & Qin, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138658 · Cited by 21
Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18
Reinforcing targeted therapeutics with phenotypic stability factors
Yaswen, P. (2014) · Cell Cycle · doi:10.4161/15384101.2014.985071 · Cited by 18
Palbociclib: A new hope in the treatment of breast cancer
Palanisamy, R. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.168988 · Cited by 19
The role of abemaciclib in treatment of advanced breast cancer
McCartney, A., Moretti, E., Sanna, G., Pestrin, M., Risi, E., Malorni, L., Biganzoli, L., & Leo, A. D. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918776925 · Cited by 22
Gastrointestinal stromal tumor – A review of clinical studies
Khoshnood, A. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219846955 · Cited by 20
STK11 is required for the normal program of ciliated cell differentiation in airways
Chu, Q., Yao, C., Qi, X., Stripp, B. R., & Tang, N. (2019) · Cell Discovery · doi:10.1038/s41421-019-0104-z · Cited by 20
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
Takahashi, M., Masuda, N., Nishimura, R., Inoue, K., Ohno, S., Iwata, H., Hashigaki, S., Muramatsu, Y., Umeyama, Y., & Toi, M. (2020) · Cancer Medicine · doi:10.1002/cam4.3091 · Cited by 19
Chen, D., Sun, X., Zhang, X., & Cao, J. (2020) · BioMed Research International · doi:10.1155/2020/9525207 · Cited by 19
Luo, C., Hou, M., Huang, C., Wu, C., Ou‐Yang, F., Li, Q.-L., Wu, C.-C., & Pan, M. (2020) · American Journal of Cancer Research · Cited by 21
Bashour, S. I., Doostan, I., Keyomarsi, K., Valero, V., Ueno, N. T., Brown, P. H., Litton, J. K., Koenig, K. B., Karuturi, M. S., Abouharb, S., et al. (2017) · Journal of Cancer · doi:10.7150/jca.18196 · Cited by 19
Myt1 Kinase: An Emerging Cell-Cycle Regulator for Cancer Therapeutics
Lang, F., Kaur, K., Zaheer, J., Ribeiro, D. L., & Yang, C. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3571 · Cited by 21
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
Ham, A., Kim, M. H., Kim, G. M., Kim, J. H., Kim, J. Y., Park, H. S., Park, S., Cho, Y. U., Park, B., Kim, S. I., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05750-y · Cited by 17
Portman, N., Chen, J., & Lim, E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.777867 · Cited by 24
Kong, P., Yang, X. M., Zhang, Y., Dong, H., Liu, X., Xu, X., Zhang, X., Shi, Y., Hou, M., & Song, B. (2022) · Journal of Oncology · doi:10.1155/2022/2260625 · Cited by 17
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
Pegram, M. D., Pietras, R. J., Dang, C. T., Murthy, R. K., Bachelot, T., Janni, W., Sharma, P., Hamilton, E. P., & Saura, C. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231187201 · Cited by 21
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
Guo, Z., Dong, R. W., Wu, Y., Dong, S., & Alahari, S. K. (2025) · Oncogene · doi:10.1038/s41388-025-03378-0 · Cited by 18
The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer
Tanaka, T., Terai, Y., Ashihara, K., Fujiwara, S., Tanaka, Y., Sasaki, H., Tsunetoh, S., & Ohmichi, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177019 · Cited by 19
Cutaneous Melanoma – A Review of Systemic Therapies
Lee, K., & Nathan, P. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3496 · Cited by 24
Long, Q., Ma, A., Zhang, H., Cao, Z., Xia, R., Lin, T., Sonpavde, G., White, R. D., Guo, J., & Pan, C.-X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02609-5 · Cited by 18
Porte, B., Carton, M., Lerebours, F., Brain, E. G. C., Loirat, D., Haroun, L., Bellesœur, A., Hamba, S. B., Kirova, Y., & Cottu, P. H. (2020) · The Breast · doi:10.1016/j.breast.2020.11.008 · Cited by 19
A Whole-Genome RNA Interference Screen for Human Cell Factors Affecting Myxoma Virus Replication
Teferi, W. M., Dodd, K., Maranchuk, R. A., Favis, N. A., & Evans, D. H. (2013) · Journal of Virology · doi:10.1128/jvi.02617-12 · Cited by 19
Lapeire, L., Hendrix, A., Lecoutere, E., Bockstal, M. V., Vandesompele, J., Maynard, D., Braems, G., Rudy, V. D. B., Muller, C., Bracke, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17592 · Cited by 25
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
Masuda, N., Mukai, H., Inoue, K., Rai, Y., Ohno, S., Mori, Y., Hashigaki, S., Muramatsu, Y., Umeyama, Y., Iwata, H., et al. (2019) · Breast Cancer · doi:10.1007/s12282-019-00970-7 · Cited by 18
Chen, F., Zhang, Z., Yu, Y., Liu, Q., & Pu, F. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5057 · Cited by 17
He, F., Zhang, Q., Chen, Y., Ge, S., Xie, Y., Sun, R., Wu, Y., & Xu, J. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5564 · Cited by 24
Agrawal, C. R., Goyal, P., Agarwal, A., Tripathi, R., Dodagoudar, C., Baghmar, S., Sharma, A. K., Batra, U., Talwar, V., Goyal, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95758-1 · Cited by 18
CDK4/6-USP51 axis regulates lung adenocarcinoma metastasis through ZEB1
Li, J., Xiao, X., Wang, H., Wang, W., Ou, Y., Wang, Z., Jiang, H., Liu, Y., Zhang, Z., & Yang, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00420-7 · Cited by 20
Han, J. M., & Jung, H. J. (2022) · Molecules · doi:10.3390/molecules27227968 · Cited by 17
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer
der Maur, P. A., Trefny, M. P., Baumann, Z., Vulin, M., Correia, A. L., Diepenbruck, M., Kramer, N., Volkmann, K., Preca, B., Ramos, P. M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101002 · Cited by 21
Flint, A. C., Mitchell, D. K., Angus, S. P., Smith, A. E., Bessler, W., Jiang, L., Mang, H. E., Li, X., Lu, Q., Rodriguez, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2854 · Cited by 18
Lee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 19
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_9 · Cited by 19
Naji, O., Ghouzlani, A., Rafii, S., Sadiqi, R. U., Kone, A.-S., Harmak, Z., Choukri, K., Kandoussi, S., Karkouri, M., & Badou, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399754 · Cited by 23
Profile of palbociclib in the treatment of metastatic breast cancer
Elbaz, M., & Ehab, M. (2016) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s83146 · Cited by 22
Palbociclib—The First of a New Class of Cell Cycle Inhibitors
Schmidt, M., & Sebastian, M. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_11 · Cited by 20
Metadata
- Authors
- Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., Los, G., & Slamon, D. J.
- Affiliations
- University of California, Los Angeles (US)
- Pfizer (United States) (US)
- Corresponding author
- Finn, Richard S
- Venue
- Breast Cancer Research
- Published
- 2009-10-29
- Volume
- 11
- Issue
- 5
- Pages
- R77-R77
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- PMC
- PMC2790859
- OpenAlex
- W2148345265
- Cited by
- 1,398
- References
- 49
- Citations by year
- 2026: 48 · 2025: 76 · 2024: 64 · 2023: 94 · 2022: 115 · 2021: 121 · 2020: 137 · 2019: 128 · 2018: 137 · 2017: 131 · 2016: 105 · 2015: 92 · 2014: 51 · 2013: 42 · 2012: 28
- FWCI
- 15.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Breast Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Defense (W81XWH)
- Russian Science Foundation
- National Institutes of Health (W81XWH)
- Jonsson Comprehensive Cancer Center
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- palbociclib, CDK4/6 inhibitors, HER2-amplified breast cancer, retinoblastoma protein phosphorylation, cyclin D1, CDKN2A, p16, G0/G1 cell cycle arrest, drug sensitivity, drug resistance, patient selection, breast cancer cell lines
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Cell Cycle, Drug Synergism, Humans, Phosphorylation, Piperazines, Pyridines, Receptors, Estrogen, Tamoxifen, Retinoblastoma Protein, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Gene Expression Profiling, Cell Line, Tumor, Cell Growth Processes, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.